#1 PRESCRIBED MIGRAINE TREATMENT IN ITS CLASS SINCE 8/6/21*

For the acute treatment of migraine
and the preventive treatment of episodic migraine in adults

5 Reasons to Choose Nurtec ODT for Your Patients

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

1 TREAT & PREVENT—ALL IN ONE[1]

- The ONLY medication indicated to both treat and prevent migraine attacks.[1,2]

2 EFFICACY THAT'S FAST & LASTS[1,3]

ACUTE TREATMENT

Delivered freedom from pain and most bothersome symptom (MBS)[1]

At 2 hours (co-primary endpoints):

- **21.2% of patients on Nurtec ODT achieved migraine pain freedom** vs 10.9% on placebo (*P*<.001).[1]
- **35.1% achieved freedom from MBS** vs 26.8% on placebo (*P*=.001).[1]

Rapid response at 1 hour[3,4]

(select secondary endpoints):

- **36.8% of patients on Nurtec ODT achieved pain relief** vs 31.2% on placebo (*P*=.0314).[3,4]
- **22.3% had returned to normal function** vs 15.8% on placebo (*P*=.0025).[3,4]

One dose treats for up to 2 days[3,4]

From 2 to 48 hours (select secondary endpoint):

- **42.2% of patients on Nurtec ODT had sustained pain relief** vs 25.2% on placebo (*P*<.0001).[3,4]

PREVENTIVE TREATMENT

Reduced monthly migraine days (MMDs)[1]

During weeks 9 through 12 (primary endpoint):

- **Patients on treatment had a 4.3-day reduction from baseline in mean MMDs** vs a 3.5-day reduction in those taking placebo (*P*=.01).[1,†]

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed and number one in new prescriptions, since 8/6/21. Data current as of 11/22.

3 86% OF PATIENTS ON NURTEC ODT DID NOT TAKE A RESCUE MEDICATION[1,‡]

Within 24 hours post-dose (select secondary endpoint) vs 71% on placebo (*P*<.001)[1,‡]

4 ADAPT TO YOUR PATIENTS' INDIVIDUAL NEEDS[1,5]

- For triggers that are predictable, unavoidable, or planned.[1,5]

5 NO ADVERSE EVENT >3% IN THE TWO PIVOTAL TRIALS[1]

- The most common adverse event (AE) with acute dosing was nausea (Nurtec ODT 2%; placebo 0.4%).[1]
- The most common AEs in the preventive study were nausea (rimegepant 2.7%; placebo 0.8%) and abdominal pain/dyspepsia (rimegepant 2.4%; placebo 0.8%).[1]

Please see study designs on the next page.

"Nurtec ODT gives me the flexibility to treat or prevent my migraines, so I can handle migraine my way."

Ellie W.
Actual Nurtec ODT patient.
Triggers: stress, menstruation.
Individual results may vary.

CGRP=calcitonin gene-related peptide
OTC=over-the-counter medications
Patients were invited to share their treatment experience.
†Analyzed using a generalized linear mixed-effects model with treatment group, preventive migraine medication use at randomization, study month, and month-by-treatment group interaction as fixed effects and participant as random effect.[2]
‡Patients who took rescue medication were included in the analysis and classified as failures.[3]

SELECT IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Please see additional Important Safety Information on the next page and click here for full Prescribing Information.

Click here to learn more

STUDY DESIGNS

For the acute treatment of migraine with or without aura in adults, Nurtec ODT was evaluated in a multi-center, double-blind, randomized, placebo-controlled study in which 1466 patients were randomized to Nurtec ODT (n=732) or placebo (n=734) and 1351 patients were evaluated for efficacy (n=669; n=682). The co-primary endpoints at 2 hours for Nurtec ODT vs placebo were pain freedom and freedom from most bothersome symptom; predefined as photophobia, phonophobia, or nausea.[1]

For the preventive treatment of episodic migraine in adults, rimegepant 75 mg was evaluated in a multi-center, double-blind, randomized, placebo-controlled study in which 747 patients were randomized to rimegepant 75 mg (n=373) or placebo (n=374) and 695 patients were evaluated for efficacy (n=348; n=347). The primary endpoint was change from baseline in the mean number of monthly migraine days during weeks 9 through 12.[1]

INDICATIONS

Nurtec ODT is indicated in adults for the:
- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

Use in Specific Populations: *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation:* The transfer of rimegepant into breastmilk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

Please click here for full Prescribing Information.

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. **2.** Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. *Lancet*. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7 **3.** Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *Lancet*. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X **4.** Lipton RB, Coric V, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg orally dissolving tablet for the acute treatment of migraine: a phase 3, double-blind, randomized, placebo-controlled trial (study 303). Abstract presented at: 61st Annual Scientific Meeting of the American Headache Society; Philadelphia, PA. Session IOR05; July 11, 2019. **5.** Health Union, LLC. *Migraine in America 2020*. Health Union, LLC; 2020.

January 2023. PP-NNT-USA-0264.

Nurtec® ODT
(rimegepant)
orally disintegrating tablets 75 mg